https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Reviews Plozasiran: A Potential First-in-Class Therapy for Familial Chylomicronemia Syndrome

FDA Reviews Plozasiran: A Potential First-in-Class Therapy for Familial Chylomicronemia Syndrome

Plozasiran significantly reduces triglyceride levels and pancreatitis risk in FCS patients, offering hope for effective treatment options.

administrator

Related Articles